+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cervical Cancer Drugs Global Market Report 2020

  • ID: 4871544
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company

FEATURED COMPANIES

  • Allergan plc
  • Amgen
  • Biocon Limited
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Merck & Co
Cervical Cancer Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global cervical cancer drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the cervical cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cervical Cancer Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Cancer Type: Squamous Cell Cancer, Adenocarcinoma 2) By Drug Type: Avastin, Bevacizumb, Blemocin, Blenoxane, Others 3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Others
  • Companies Mentioned: F. Hoffmann-La Roche Ltd, Hetero, GlaxoSmithKline, Eli Lilly and Company, Pfizer
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan plc
  • Amgen
  • Biocon Limited
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Merck & Co
1. Executive Summary

2. Cervical Cancer Drugs Market Characteristics

3. Cervical Cancer Drugs Market Size And Growth
3.1. Global Cervical Cancer Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Cervical Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Cervical Cancer Drugs Market Segmentation
4.1. Global Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Squamous Cell Cancer
  • Adenocarcinoma
4.2. Global Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Avastin
  • Bevacizumb
  • Blemocin
  • Blenoxane
  • Others
4.3. Global Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others
5. Cervical Cancer Drugs Market Regional And Country Analysis
5.1. Global Cervical Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Cervical Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Cervical Cancer Drugs Market
6.1. Asia-Pacific Cervical Cancer Drugs Market Overview
6.2. Asia-Pacific Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.4. Asia-Pacific Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Cervical Cancer Drugs Market
7.1. China Cervical Cancer Drugs Market Overview
7.2. China Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.4. China Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Cervical Cancer Drugs Market
8.1. India Cervical Cancer Drugs Market Overview
8.2. India Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.4. India Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Cervical Cancer Drugs Market
9.1. Japan Cervical Cancer Drugs Market Overview
9.2. Japan Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.4. Japan Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Cervical Cancer Drugs Market
10.1. Australia Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.3. Australia Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Cervical Cancer Drugs Market
11.1. Indonesia Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.3. Indonesia Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Cervical Cancer Drugs Market
12.1. South Korea Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.3. South Korea Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Cervical Cancer Drugs Market
13.1. Western Europe Cervical Cancer Drugs Market Overview
13.2. Western Europe Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.4. Western Europe Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Cervical Cancer Drugs Market
14.1. UK Cervical Cancer Drugs Market Overview
14.2. UK Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.4. UK Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Cervical Cancer Drugs Market
15.1. Germany Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.3. Germany Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Cervical Cancer Drugs Market
16.5. France Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.6. France Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.7. France Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Cervical Cancer Drugs Market
17.1. Eastern Europe Cervical Cancer Drugs Market Overview
17.2. Eastern Europe Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.4. Eastern Europe Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Cervical Cancer Drugs Market
18.1. Russia Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.3. Russia Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Cervical Cancer Drugs Market
19.1. North America Cervical Cancer Drugs Market Overview
19.2. North America Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.4. North America Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Cervical Cancer Drugs Market
20.1. USA Cervical Cancer Drugs Market Overview
20.2. USA Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.4. USA Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Cervical Cancer Drugs Market
21.1. South America Cervical Cancer Drugs Market Overview
21.2. South America Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.4. South America Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Cervical Cancer Drugs Market
22.1. Brazil Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.3. Brazil Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Cervical Cancer Drugs Market
23.1. Middle East Cervical Cancer Drugs Market Overview
23.2. Middle East Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.4. Middle East Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Cervical Cancer Drugs Market
24.1. Africa Cervical Cancer Drugs Market Overview
24.2. Africa Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Cervical Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.4. Africa Cervical Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Cervical Cancer Drugs Market Competitive Landscape And Company Profiles
25.1. Cervical Cancer Drugs Market Competitive Landscape
25.2. Cervical Cancer Drugs Market Company Profiles
25.2.1. F. Hoffmann-La Roche Ltd
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Hetero
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. GlaxoSmithKline
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Eli Lilly and Company
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Pfizer
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Cervical Cancer Drugs Market

27. Cervical Cancer Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Cervical Cancer Drugs Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan plc
  • Amgen
  • Biocon Limited
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Merck & Co
The cervical cancer drugs market consists of sales of cervical cancer drugs used for the treatment of cervical cancer in women. The cervical cancer is the medical condition in which there is a tumor formation in the lower portion of uterus which is known as cervix.

The global cervical cancer drugs market was valued at about $15.3 billion in 2018 and is expected to grow to $17.9 billion at a CAGR of 4.0% through 2022.

North America was the largest region in the cervical cancer drugs market in 2018. This region is expected to remain the largest during the next five years. The cervical cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market. Women with HIV positive have a greater risk of cervical cancer than the general population. Nearly 18 million women have tested HIV positive globally, HIV weakens the immune system which increases the likelihood of cervical cancer. Women with HIV have an increased chance of being diagnosed with cervical cancer because the count of the protein CD4 goes down. According to a survey conducted by the National cancer institute, in 2017, a person with HIV is three time as likely to be diagnosed with cervical cancer.

The lack of awareness and other misconceptions about cervical cancers hinder the growth of the cervical cancer drugs market. A lot of cervical cancer-related deaths among women are due to late diagnosis of disease. The lack of awareness leads to avoidance about the disease; this ignorance causes delayed diagnosis and medication/treatment. In 2017, a study was conducted at the Bowen University Teaching Hospital (BUTH), in Nigeria, about 318 women from the general outpatient clinic were interviewed to assess the level of awareness of cervical cancer. The level of awareness for cervical cancer was 22.6% and 17.9% for screening tests, with major sources of information being from health talks and hospital staffs.

The cervical cancer drugs market is experiencing a number of significant trends that helps in efficient and targeted treatment of the disease including advances in drug delivery. One such trend is the use of drugs that can be delivered directly from the vagina such as drugs using vaginal formulations as gels, creams, pessaries, rings, films and tablets. These drugs ease the localized treatment of cervical cancer. The formulation of these drugs is in such a way that they get easily absorbed into vaginal tissue and reach the site of action. For instance, companies introduced vaginal gels such as Cidofovir gel and 851B Gel into the market to treat cervical cancer. As per the reports by International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)'s Clinical Trials Registry, 851B Gel is in trial phase. Whereas Cidofovir gel, sold under the brand name Vistide, is already a success in the market. In addition to the above mentioned gels, drugs such as ISA101, AGEN2034 and Z-100 are in pipeline and promise growth to the cervical cancer drugs market.

The U.S. Food And Drug Administration (FDA) regulates the safety and effectiveness of cancer drugs in the market. The Oncologic Drugs Advisory Committee process evaluation and clinical trials of cancer drugs requested by FDA. The Division of Oncology Products 1 (DOP1) regulates investigation, application, licensing of new drug for gynecological cancers. Various clinical trials are done for approval of cervical cancer drugs. Under the title 21CFR314, subpart H regulates the approval of new drugs that are for serious illness.

In January 2019, Bristol-Myers Squibb, an American biopharmaceutical company acquired Celgene for $74 billion. This acquisition will enable the Bristol-Myers Squibb to hold a strong position in oncology, immunology and inflammation and cardiovascular diseases drugs market. Celgene is an American biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases globally.

Major players in the market are F. Hoffmann-La Roche Ltd, Hetero, GlaxoSmithKline, Eli Lilly and Company, Pfizer
Note: Product cover images may vary from those shown
  • F. Hoffmann-La Roche Ltd
  • Hetero
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Pfizer
  • Alnylam Pharmaceuticals
  • Allergan plc
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Novartis AG
  • AstraZeneca plc
  • Celgene
  • Merck & Co
  • Amgen
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll